Technical Analysis for AGLE - Aeglea BioTherapeutics, Inc.

Grade Last Price % Change Price Change
grade F 8.25 0.61% 0.05
AGLE closed up 0.61 percent on Tuesday, March 19, 2019, on 65 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical AGLE trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Resistance Bearish 0.00%
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 19 Inside Day Range Contraction 0.00%
Mar 18 20 DMA Resistance Bearish 0.61%
Mar 18 50 DMA Resistance Bearish 0.61%
Mar 18 Bollinger Band Squeeze Range Contraction 0.61%
Mar 18 Outside Day Range Expansion 0.61%
Mar 15 50 DMA Resistance Bearish 3.13%
Mar 15 Fell Below 20 DMA Bearish 3.13%
Mar 15 MACD Bearish Signal Line Cross Bearish 3.13%

Older signals for AGLE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer; and AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies. The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors; and AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria. It has a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
Chemistry Biopharmaceutical Cancer Solid Tumors Organic Chemistry Inborn Errors Of Metabolism
Is AGLE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.0
52 Week Low 6.31
Average Volume 159,397
200-Day Moving Average 8.9348
50-Day Moving Average 8.4114
20-Day Moving Average 8.2785
10-Day Moving Average 8.193
Average True Range 0.387
ADX 18.0
+DI 12.575
-DI 21.5289
Chandelier Exit (Long, 3 ATRs ) 7.549000000000001
Chandelier Exit (Short, 3 ATRs ) 8.831
Upper Bollinger Band 8.6098
Lower Bollinger Band 7.9472
Percent B (%b) 0.46
BandWidth 8.003865
MACD Line -0.0319
MACD Signal Line -0.026
MACD Histogram -0.0059
Fundamentals Value
Market Cap 135.73 Million
Num Shares 16.5 Million
EPS -1.81
Price-to-Earnings (P/E) Ratio -4.56
Price-to-Sales 15.71
Price-to-Book 1.22
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.63
Resistance 3 (R3) 8.60 8.45 8.56
Resistance 2 (R2) 8.45 8.35 8.46 8.54
Resistance 1 (R1) 8.35 8.30 8.40 8.38 8.52
Pivot Point 8.20 8.20 8.23 8.21 8.20
Support 1 (S1) 8.10 8.10 8.15 8.13 7.98
Support 2 (S2) 7.95 8.05 7.96 7.96
Support 3 (S3) 7.85 7.95 7.94
Support 4 (S4) 7.88